Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

TELO US Equity

Telomir Pharmaceuticals, Inc.Health Care · Pharmaceutical Preparations · CIK 1971532 · FY ends Dec 31
$1.08
+0.02 (+1.89%)
USD · as of 2026-08-18 · marketstack

Legal & controls

3 of 3 annual reports readable here

Item 3 and Item 9A as filed · every verdict is the registrant’s own sentence, printed below it · a filing that fails an extraction gate reads “not extracted”

Fiscal yearFiledItem 3ICFRdisclosure controlsmaterial weaknessFiling
2025-12-312026-03-17none statedeffectiveeffectiveremediated (prior year)EDGAR

Item 3 · None

Item 9A · ICFR · Based on the criteria established by COSO management concluded that the Company’s internal control over financial reporting was effective as of December 31, 2025.

Item 9A · disclosure controls · The Certifying Officers have concluded, based on their evaluation as of the end of the period covered by this Report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.

Item 9A · material weakness · Management believes these enhancements were sufficient to remediate previously identified material weaknesses.

2024-12-312025-02-04none statedeffectiveeffectiveremediated (prior year)EDGAR

Item 3 · None

Item 9A · ICFR · Based on the criteria established by COSO management concluded that the Company’s internal control over financial reporting was effective as of December 31, 2024.

Item 9A · disclosure controls · The Certifying Officers have concluded, based on their evaluation as of the end of the period covered by this Report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.

Item 9A · material weakness · Management believes these enhancements were sufficient to remediate previously identified material weaknesses.

2023-12-312024-03-29none statednot extractedNOT effectivenone in Item 9AEDGAR

Item 3 · None

Item 9A · disclosure controls · Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of the end of fiscal year 2023.

3 of 3 annual reports on record have their filing text cached on this host; the rest are listed with their EDGAR link and no extraction, because this surface never fetches from SEC on a page load.

  • Item 3 and Item 9A are located in the filing HTML already cached on this host and read with the same line-anchored item matcher and largest-gap body disambiguation the filing-narrative pass uses for Item 1A and Item 7 — no fetch, no model, no summarization.
  • A heading is accepted as a section only when it is not a table-of-contents row (a trailing page number), not a quoted reference in prose, and names its own section; the span must then clear a per-item length band and carry readable text after the heading. Anything that fails a gate is served as 'not extracted' with the reason — never as a default value.
  • An effectiveness conclusion is read only from a sentence that names its own control set (disclosure controls and procedures, or internal control over financial reporting) and states an outcome. Conditional sentences — the standard limitations paragraph and forward-looking remediation language — are excluded, because they are hypotheses rather than conclusions.
  • When a filing's own sentences disagree — an effective conclusion beside an unremediated material-weakness disclosure, or two conclusions of opposite sign — no verdict is asserted. A wrong 'controls were effective' reading is worse than no reading.
  • Every verdict is shown beside the verbatim sentence it was read from. The excerpt is the filing's own words, capped at 1,200 characters; the filing itself is one link away.